Singh N K, Gupta A
Department of Medicine, Banaras Hindu University, Varanasi.
J Assoc Physicians India. 1996 Jan;44(1):22-4.
Forty-six patients of Guillain-Barre' Syndrome were randomized to receive either prednisolone (40 mg daily for 2 weeks and then tapered off) or placebo. The patients were followed up for 6 months and were assessed on an objective scale of disability. The improvement in mean disability grade was significantly better at 2 weeks and 4 weeks in the placebo group as compared to those who received corticosteroids. The difference persisted at 24 weeks, but was statistically insignificant. A greater proportion of patients in the placebo group had improved by at least 1 disability grade at all points of time. The group of patients treated with steroids took twice as long to improve by 1 disability grade as compared to those in the placebo group. At 6 months, 41.7% of the patients in the steroid group had recovered almost completely (good outcome) as compared to 54.5% of the patients is the placebo group. Corticosteroids, therefore, do not appear to benefit GBS patients, and may in fact, delay the recovery from acute illness.
46例格林-巴利综合征患者被随机分为两组，分别接受泼尼松龙治疗（每日40毫克，持续2周，然后逐渐减量）或安慰剂治疗。对患者进行了6个月的随访，并根据客观残疾量表进行评估。与接受皮质类固醇治疗的患者相比，安慰剂组在2周和4周时平均残疾等级的改善情况明显更好。这种差异在24周时仍然存在，但无统计学意义。在所有时间点，安慰剂组中至少改善1个残疾等级的患者比例更高。与安慰剂组相比，接受类固醇治疗的患者改善1个残疾等级所需的时间是其两倍。在6个月时，类固醇组41.7%的患者几乎完全康复（良好结局），而安慰剂组这一比例为54.5%。因此，皮质类固醇似乎对格林-巴利综合征患者没有益处，实际上可能会延迟急性疾病的康复。
